drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Genetically engineered natural killer cells expressing an anti-CD19 chimeric antigen receptor to target and deplete CD19+ B cells via NK cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered natural killer cells expressing an anti‑CD19 chimeric antigen receptor bind CD19 on B cells and trigger NK cell activation and cytotoxicity (perforin/granzyme), leading to targeted depletion of CD19+ B cells and reduction of pathogenic humoral responses.
drug_name
KN5501 (anti-CD19 CAR NK cells)
nct_id_drug_ref
NCT06318533